CN1151377C - 诊断及治疗鳞状细胞癌的方法 - Google Patents

诊断及治疗鳞状细胞癌的方法 Download PDF

Info

Publication number
CN1151377C
CN1151377C CNB961992484A CN96199248A CN1151377C CN 1151377 C CN1151377 C CN 1151377C CN B961992484 A CNB961992484 A CN B961992484A CN 96199248 A CN96199248 A CN 96199248A CN 1151377 C CN1151377 C CN 1151377C
Authority
CN
China
Prior art keywords
antibody
sequence
lymph node
molecule
node metastasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB961992484A
Other languages
English (en)
Chinese (zh)
Other versions
CN1207811A (zh
Inventor
����-����ġ���͢��
卡尔-海因茨·海德
冈瑟·阿道夫
埃林伯格·奥斯特曼
埃里克·帕特泽尔特
马利斯·斯普罗尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karlsruhe Research Center
Boehringer Ingelheim International GmbH
Original Assignee
Karlsruhe Research Center
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/de
Application filed by Karlsruhe Research Center, Boehringer Ingelheim International GmbH filed Critical Karlsruhe Research Center
Publication of CN1207811A publication Critical patent/CN1207811A/zh
Application granted granted Critical
Publication of CN1151377C publication Critical patent/CN1151377C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB961992484A 1995-12-06 1996-12-05 诊断及治疗鳞状细胞癌的方法 Expired - Fee Related CN1151377C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19545472.3 1995-12-06
DE19545472A DE19545472A1 (de) 1995-12-06 1995-12-06 Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19615074.4 1996-04-17
DE19615074 1996-04-17

Publications (2)

Publication Number Publication Date
CN1207811A CN1207811A (zh) 1999-02-10
CN1151377C true CN1151377C (zh) 2004-05-26

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB961992484A Expired - Fee Related CN1151377C (zh) 1995-12-06 1996-12-05 诊断及治疗鳞状细胞癌的方法

Country Status (25)

Country Link
EP (1) EP0865609B1 (enExample)
JP (1) JP2000502067A (enExample)
KR (1) KR100473824B1 (enExample)
CN (1) CN1151377C (enExample)
AR (1) AR004360A1 (enExample)
AT (1) ATE235056T1 (enExample)
AU (1) AU726704B2 (enExample)
BG (1) BG62985B1 (enExample)
BR (1) BR9611901A (enExample)
CA (1) CA2239709A1 (enExample)
CO (1) CO4520233A1 (enExample)
CZ (1) CZ174198A3 (enExample)
DE (1) DE59610248D1 (enExample)
DK (1) DK0865609T3 (enExample)
EE (1) EE03783B1 (enExample)
ES (1) ES2190484T3 (enExample)
MX (1) MX9804459A (enExample)
NO (1) NO319903B1 (enExample)
NZ (1) NZ324314A (enExample)
PL (1) PL184521B1 (enExample)
PT (1) PT865609E (enExample)
SK (1) SK284378B6 (enExample)
TR (1) TR199801027T2 (enExample)
UY (1) UY24389A1 (enExample)
WO (1) WO1997021104A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
CN1541226A (zh) * 2001-05-18 2004-10-27 ���ָ��Ӣ��ķ�������Ϲ�˾ CD44v6特异性的抗体
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
JP5763105B2 (ja) * 2010-02-04 2015-08-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 頭頸部扁平上皮癌の治療に使用されるｃｄ４４に対するモノクローナル抗体
US9218450B2 (en) 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
EP3755717A4 (en) * 2018-02-22 2022-01-26 Multitude Inc. THERAPEUTIC ANTIBODY AND USES THEREOF
IL317000A (en) 2022-05-25 2025-01-01 Akiram Therapeutics Ab Antibodies against CD44V6 and their use in the treatment of cancers that overexpress CD44V6

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69406664T2 (de) * 1993-06-18 1998-06-04 Biotie Therapies Oy Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6
WO1995000851A1 (de) * 1993-06-22 1995-01-05 Boehringer Ingelheim International Gmbh Verfahren zur diagnose und analyse von tumoren
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти

Also Published As

Publication number Publication date
NO319903B1 (no) 2005-09-26
KR19990071952A (ko) 1999-09-27
MX9804459A (es) 1998-09-30
JP2000502067A (ja) 2000-02-22
EE03783B1 (et) 2002-06-17
CZ174198A3 (cs) 1999-02-17
EE9800164A (et) 1998-12-15
DE59610248D1 (de) 2003-04-24
UY24389A1 (es) 2001-10-25
AR004360A1 (es) 1998-11-04
BR9611901A (pt) 1999-03-02
CA2239709A1 (en) 1997-06-12
KR100473824B1 (ko) 2005-09-30
SK284378B6 (sk) 2005-02-04
NO982588D0 (no) 1998-06-05
PL327066A1 (en) 1998-11-23
ATE235056T1 (de) 2003-04-15
NZ324314A (en) 2000-02-28
HK1011560A1 (en) 1999-07-16
EP0865609A1 (de) 1998-09-23
DK0865609T3 (da) 2003-06-23
AU1177397A (en) 1997-06-27
BG62985B1 (bg) 2000-12-29
AU726704B2 (en) 2000-11-16
PT865609E (pt) 2003-08-29
NO982588L (no) 1998-08-05
ES2190484T3 (es) 2003-08-01
CN1207811A (zh) 1999-02-10
SK73698A3 (en) 1999-01-11
BG102513A (en) 1999-02-26
TR199801027T2 (xx) 1998-10-21
WO1997021104A1 (de) 1997-06-12
CO4520233A1 (es) 1997-10-15
PL184521B1 (pl) 2002-11-29
EP0865609B1 (de) 2003-03-19

Similar Documents

Publication Publication Date Title
CN1229391C (zh) 涉及α6β4整联蛋白的人胃肠上皮肿瘤抗原的抗体
CN1201005C (zh) 特异性检测癌细胞的抗原结合片段、编码所述片段的dna、以及它们在预防和检测癌症上的用途
CN100344970C (zh) 结合前列腺特异性膜抗原胞外域的抗体或其抗原结合部分、包含它们的试剂盒及其用途
CN1192796C (zh) 联合应用抗血管生成和免疫治疗以治疗肿瘤和转移的方法
CN1826138A (zh) Rg1抗体及其用途
CN1151377C (zh) 诊断及治疗鳞状细胞癌的方法
CN101035809A (zh) 抗tag－72的人源化单克隆抗体
CN1809592A (zh) 识别n－乙醇酰gm3神经节苷脂的重组抗体和片段以及其在肿瘤诊断和治疗上的应用
CN101044242A (zh) 肿瘤特异性抗体
CN1235639A (zh) 重新构建的人抗hm1.24抗体
CN1761482A (zh) 与胰腺癌相关的抗原、针对它的抗体以及诊断和治疗方法
CN1604966A (zh) 直接靶定的结合蛋白
CN1795009A (zh) 抗－cd33抗体和使用其治疗急性髓性白血病的方法
CN1816352A (zh) 使用一种免疫毒素治疗癌症的方法
CN1547590A (zh) 人源化抗-LT-β-R抗体
CN1823163A (zh) 针对胰岛素样生长因子ⅰ受体的抗体及其应用
CN1596313A (zh) 人源化的胶原抗体及相关方法
CN101076542A (zh) 特异性针对肝细胞癌和其他癌的抗体及其用途
CN1642983A (zh) 抗C5aR抗体及其应用
CN1551886A (zh) 用于选择性癌症治疗的特异性人抗体
CN1493597A (zh) 分离树突状细胞膜蛋白基因
CN1151184A (zh) 对细胞周期非依赖的神经胶质瘤表面抗原特异的人单克隆抗体
CN1649901A (zh) 人癌胚抗原(cea)的特异性抗体片段
CN1297566C (zh) 编码新rg1多肽的dna
CN1849337A (zh) 利用igsf9和liv－1的、用于治疗癌症的组合物及方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee